Alto Neuroscience

Alto Neuroscience company information, Employees & Contact Information

Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

Company Details

Employees
77
Founded
-
Address
Mountain View, California 94041, Us
Email
in****@****nce.com
Industry
Biotechnology
Keywords
(AWS).
HQ
Mountain View, California
Looking for a particular Alto Neuroscience employee's phone or email?

Alto Neuroscience Questions

News

Alto Neuroscience to Participate in Upcoming Investor Conferences - Yahoo Finance

Alto Neuroscience to Participate in Upcoming Investor Conferences Yahoo Finance

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Yahoo Finance

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting Yahoo Finance

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights Yahoo Finance

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - Business Wire

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia Business Wire

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia - Yahoo Finance

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia Yahoo Finance

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression - Yahoo Finance

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression Yahoo Finance

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors - Business Wire

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors Business Wire

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Yahoo Finance

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway Yahoo Finance

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Yahoo Finance

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker Yahoo Finance

Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences Business Wire

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203 - Business Wire

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203 Business Wire

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights Business Wire

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights Business Wire

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - Business Wire

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial Business Wire

Alto Neuroscience Advances Four Phase 2 Trials With Precision Psychiatry Focus - Psychiatric Times

Alto Neuroscience Advances Four Phase 2 Trials With Precision Psychiatry Focus Psychiatric Times

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights Yahoo Finance

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering - Business Wire

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering Business Wire

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia - Business Wire

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia Business Wire

User - FinancialContent

User FinancialContent

Alto Neuroscience Announces $60 Million in Additional Financing - Business Wire

Alto Neuroscience Announces $60 Million in Additional Financing Business Wire

Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry - Business Wire

Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry Business Wire

Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing - GlobeNewswire

Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing GlobeNewswire

Top Alto Neuroscience Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant